{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:17:42Z","timestamp":1783693062973,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s43441-026-00955-7","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T13:54:51Z","timestamp":1774446891000},"page":"965-971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioequivalence of Generic Semi-solid Topical Dermatological Drug Products: Scientific and Regulatory Perspective from Japan\u2019s 2025 Guidelines"],"prefix":"10.1007","volume":"60","author":[{"given":"Hiroyuki","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Kasuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Kuribayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokio","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Goda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"1","key":"955_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/nyas.13347","volume":"1407","author":"L Hussaarts","year":"2017","unstructured":"Hussaarts L, M\u00fchlebach S, Shah VP, McNeil S, Borchard G, Fl\u00fchmann B, et al. Equivalence of complex drug products: advances in and challenges for current regulatory frameworks. Ann N Y Acad Sci. 2017;1407(1):39\u201349.","journal-title":"Ann N Y Acad Sci"},{"key":"955_CR2","doi-asserted-by":"crossref","unstructured":"Shah VP, Maibach HI, Jenner J. Topical drug bioavailability, bioequivalence, and penetration. Berlin: Springer; 2015.","DOI":"10.1007\/978-1-4939-1289-6"},{"issue":"1","key":"955_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.14662","volume":"1502","author":"K Klein","year":"2021","unstructured":"Klein K, Borchard G, Shah VP, Fl\u00fchmann B, McNeil SE, de Vlieger JSB. A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways. Ann N Y Acad Sci. 2021;1502(1):5\u201313.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"955_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s43441-020-00114-6","volume":"54","author":"S Lunawat","year":"2020","unstructured":"Lunawat S, Bhat K. Complex generic products: insight of current regulatory frameworks in US, EU and Canada and the need of harmonisation. Ther Innov Regul Sci. 2020;54(5):991\u20131000.","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"955_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000330491","volume":"25","author":"R Holmgaard","year":"2012","unstructured":"Holmgaard R, Benfeldt E, Bangsgaard N, Sorensen JA, Brosen K, Nielsen F, et al. Probe depth matters in dermal microdialysis sampling of benzoic acid after topical application: an ex vivo study in human skin. Skin Pharmacol Physiol. 2012;25(1):9\u201316.","journal-title":"Skin Pharmacol Physiol"},{"key":"955_CR6","doi-asserted-by":"publisher","first-page":"125214","DOI":"10.1016\/j.ijpharm.2025.125214","volume":"671","author":"A Gaiser","year":"2025","unstructured":"Gaiser A, Lunter D. Investigation of the suitability of confocal Raman spectroscopy for the demonstration of bioequivalence of topical products. Int J Pharm. 2025;671:125214.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"955_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijpharm.2017.06.063","volume":"529","author":"SF Cordery","year":"2017","unstructured":"Cordery SF, Pensado A, Chiu WS, Shehab MZ, Bunge AL, Delgado-Charro MB, et al. Topical bioavailability of diclofenac from locally-acting, dermatological formulations. Int J Pharm. 2017;529(1\u20132):55\u201364.","journal-title":"Int J Pharm"},{"issue":"4","key":"955_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s13318-025-00952-5","volume":"50","author":"M Kasuga","year":"2025","unstructured":"Kasuga M, Kuwana K, Kuribayashi R. Regulation for the bioequivalence evaluation of generic topical dermatological drug products in Japan. Eur J Drug Metab Pharmacokinet. 2025;50(4):353\u201361.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"10","key":"955_CR9","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/archderm.1987.01660340074023","volume":"123","author":"RB Stoughton","year":"1987","unstructured":"Stoughton RB. Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol. 1987;123(10):1312\u20134.","journal-title":"Arch Dermatol"},{"issue":"1","key":"955_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/archderm.1985.01660010067020","volume":"121","author":"RC Cornell","year":"1985","unstructured":"Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol. 1985;121(1):63\u20137.","journal-title":"Arch Dermatol"},{"key":"955_CR11","unstructured":"EMA. Guideline on quality and equivalence of locally applied, locally acting cutaneous products European Medicines Agency; 2024."},{"key":"955_CR12","unstructured":"US-FDA. Draft guidance on topical dermatologic corticosteroids: In Vivo bioequivalence. U.S. Food and Drug Administration; 2023."},{"key":"955_CR13","unstructured":"US-FDA. Guidance on residual drug in transdermal and related drug delivery systems. U.S. Food and Drug Administration; 2011."},{"issue":"6","key":"955_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1517\/17425247.2016.1140146","volume":"13","author":"J Hadgraft","year":"2016","unstructured":"Hadgraft J, Lane ME. Drug crystallization\u2014implications for topical and transdermal delivery. Expert Opin Drug Deliv. 2016;13(6):817\u201330.","journal-title":"Expert Opin Drug Deliv"},{"key":"955_CR15","doi-asserted-by":"crossref","unstructured":"Lazar M, Zhang AD, Vashi NA. Topical treatments in atopic dermatitis: an expansive review. J Clin Med. 2024;13(8).","DOI":"10.3390\/jcm13082185"},{"issue":"4","key":"955_CR16","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s11096-023-01569-x","volume":"45","author":"C Alves","year":"2023","unstructured":"Alves C, Penedones A, Mendes D, Batel Marques F. Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis. Int J Clin Pharm. 2023;45(4):830\u20138.","journal-title":"Int J Clin Pharm"},{"key":"955_CR17","doi-asserted-by":"crossref","unstructured":"Montero-Vilchez T, Segura-Fern\u00e1ndez-Nogueras MV, P\u00e9rez-Rodr\u00edguez I, Soler-Gongora M, Martinez-Lopez A, Fern\u00e1ndez-Gonz\u00e1lez A et al. Skin barrier function in psoriasis and atopic dermatitis: transepidermal water loss and temperature as useful tools to assess disease severity. J Clin Med. 2021;10(2).","DOI":"10.3390\/jcm10020359"},{"issue":"12","key":"955_CR18","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1194\/jlr.R700013-JLR200","volume":"48","author":"KR Feingold","year":"2007","unstructured":"Feingold KR. Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J Lipid Res. 2007;48(12):2531\u201346.","journal-title":"J Lipid Res"},{"key":"955_CR19","doi-asserted-by":"crossref","unstructured":"Jin X, Imran M, Mohammed Y. Topical semisolid products-understanding the impact of metamorphosis on skin penetration and physicochemical properties. Pharmaceutics. 2022;14(11).","DOI":"10.3390\/pharmaceutics14112487"},{"key":"955_CR20","unstructured":"OECD. Test No. 428: Skin Absorption: In Vitro Method. 2004."},{"key":"955_CR21","unstructured":"OECD. Test No. 427: Skin Absorption: In Vivo Method. 2004."},{"key":"955_CR22","unstructured":"Agency EM. Guideline on quality and equivalence of locally applied, locally acting cutaneous products. EMA; 2024."},{"key":"955_CR23","doi-asserted-by":"publisher","first-page":"124398","DOI":"10.1016\/j.ijpharm.2024.124398","volume":"661","author":"D Louren\u00e7o","year":"2024","unstructured":"Louren\u00e7o D, Miranda M, Sousa JJ, Vitorino C. Therapeutic-driven framework for bioequivalence assessment of complex topical generic drug products. Int J Pharm. 2024;661:124398.","journal-title":"Int J Pharm"},{"key":"955_CR24","unstructured":"US-FDA. Draft Guidance for Industry: Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs. 2022."},{"key":"955_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13601-019-0262-y","volume":"9","author":"KY Baumann","year":"2019","unstructured":"Baumann KY, Church MK, Clough GF, Quist SR, Schmelz M, Skov PS, et al. Skin microdialysis: methods, applications and future opportunities-an EAACI position paper. Clin Transl Allergy. 2019;9:24.","journal-title":"Clin translational allergy"},{"issue":"11","key":"955_CR26","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1023\/A:1018922123774","volume":"11","author":"JM Ault","year":"1994","unstructured":"Ault JM, Riley CM, Meltzer NM, Lunte CE. Dermal microdialysis sampling in vivo. Pharm Res. 1994;11(11):1631\u20139.","journal-title":"Pharm Res"},{"key":"955_CR27","doi-asserted-by":"crossref","unstructured":"Darvin ME. Optical methods for non-invasive determination of skin penetration: current trends, advances, possibilities, prospects, and translation into in vivo human studies. Pharmaceutics. 2023;15(9).","DOI":"10.3390\/pharmaceutics15092272"},{"key":"955_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.addr.2020.03.003","volume":"153","author":"AM Pena","year":"2020","unstructured":"Pena AM, Chen X, Pence IJ, Bornschl\u00f6gl T, Jeong S, Gr\u00e9goire S, et al. Imaging and quantifying drug delivery in skin\u2014part 2: fluorescence andvibrational spectroscopic imaging methods. Adv Drug Deliv Rev. 2020;153:147\u201368.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-00955-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:49:41Z","timestamp":1783691381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-00955-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["955"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-00955-7","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The views expressed in this article are those of the authors and do not necessarily reflect the official views of their respective organizations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}